Welcome to our dedicated page for Arrivent Biopharma SEC filings (Ticker: AVBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading an oncology biotech filing can feel like decoding lab notes—especially when ArriVent BioPharma’s 10-K dives deep into EGFR mutation biology and multi-year trial costs. If you have ever searched for “ArriVent BioPharma SEC filings explained simply,” this page delivers the clarity you need.
Stock Titan’s AI-powered engine extracts the numbers and narratives that matter: from cash-runway projections hidden in footnotes to licensing royalty tiers linked to firmonertinib. Whether you are comparing one quarter’s R&D burn to the next in an “ArriVent BioPharma quarterly earnings report 10-Q filing” or scanning Form 4 data to spot management confidence, our platform translates dense disclosures into plain language and real-time alerts.
Every submission—from an 8-K announcing Phase 3 readouts to the proxy statement outlining executive compensation—is here the moment EDGAR posts it. Use the quick-view tiles to:
- Track “ArriVent BioPharma insider trading Form 4 transactions” and receive instant notifications
- Dive into “ArriVent BioPharma annual report 10-K simplified” summaries that highlight trial timelines, cash usage, and key risk factors
- Review “ArriVent BioPharma 8-K material events explained” for licensing deals or FDA designations
- See board-level decisions on dilution or options inside the “ArriVent BioPharma proxy statement executive compensation” section
Need context fast? Select AI Synopsis to understand how a new antibody-drug conjugate partnership may change revenue projections, or ask natural questions like “understanding ArriVent BioPharma SEC documents with AI” and get an instant, cited answer. No more trawling through appendices—just actionable information that supports decisions, whether you are a portfolio manager scrutinizing cash burn or a scientist tracking firmonertinib’s regulatory path.
ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and α-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).
At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of ≥30%—the study’s threshold for overall response—occurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded ≥30% tumor reduction, underscoring central-nervous-system activity.
Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.
Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed “filed” for Exchange Act purposes.
ArriVent BioPharma (NASDAQ:AVBP) submitted a routine Form 4 on 28 June 2025 reporting an insider transaction by director Merdad Parsey.
According to the filing, Parsey acquired 15,502 non-qualified stock options on 18 June 2025 at an exercise price of $24.89 per share. The options become exercisable on 18 June 2026 and expire on 17 June 2035. No common shares were sold or purchased outright, and the transaction was reported as direct ownership. After the grant, Parsey holds an additional 15,502 derivative securities linked to AVBP common stock.
No other material changes, sales, or new share ownership percentages were disclosed in this filing.
Form 4 filing reveals that Kristine Peterson, Director at ArriVent BioPharma, was granted 15,502 non-qualified stock options on June 18, 2025. The options have the following key terms:
- Exercise price set at $24.89 per share
- Exercisable starting June 18, 2026
- Expiration date of June 17, 2035
- Underlying security is ArriVent BioPharma common stock
The options were acquired at a price of $0.00, indicating a compensation grant. The filing was signed by James Kastenmayer as attorney-in-fact for Peterson on June 20, 2025. This equity compensation aligns the director's interests with shareholders through long-term stock ownership potential.
ArriVent BioPharma director John Hohneker received a non-qualified stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 15,502 stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Total cost basis of $0.00 as this was a compensation grant
The transaction was reported via Form 4 filing and executed through attorney-in-fact James Kastenmayer. This equity-based compensation aligns the director's interests with shareholders and represents a standard component of non-employee director compensation.
ArriVent BioPharma director Chris Nolet received a new stock option grant on June 18, 2025. The transaction details include:
- Granted 15,502 non-qualified stock options to purchase common stock
- Exercise price set at $24.89 per share
- Options become exercisable on June 18, 2026
- Options expire on June 17, 2035
- Zero cost basis for the options grant
This Form 4 filing, signed by James Kastenmayer as attorney-in-fact, represents a standard director compensation equity grant. The options provide Nolet with long-term alignment with shareholder interests through a 10-year exercise window, subject to a one-year vesting requirement.
FAQ
What is the current stock price of Arrivent Biopharma (AVBP)?
What is the market cap of Arrivent Biopharma (AVBP)?
What is the core focus of ArriVent BioPharma Inc?
How does ArriVent generate value in the biopharmaceutical space?
What makes firmonertinib unique as a treatment option?
Which market segments does ArriVent primarily address?
How does ArriVent differentiate itself from competitors?
What role do strategic partnerships play in ArriVent's business model?
What is the significance of the regulatory designations received by firmonertinib?
How is ArriVent positioned within the oncology drug development landscape?
